A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
← catalyst calendarNCT07444489 · readout in 1,742 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
201estimated
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-16 | actual | When the study began enrolling |
| Primary completion | 2031-05-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-05-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Antibody-mediated Rejection
- Microvascular Inflammation
Intervention
- Drug: Felzartamab — also filed as MOR202, MOR03087, TJ202, HIB202, BIIB148
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESI)
measured From first dose of study drug up to end of study follow-up (Up to Week 204)
Number of Participants who Discontinue Treatment due to an AE
measured From first dose of study drug up to end of study follow-up (Up to Week 204)
Number of Participants with Clinically Significant Laboratory, Vital Signs and Electrocardiograms (ECGs) Abnormalities
measured From first dose of study drug up to end of trial visit (up to Week 200)
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed